Scarica l'app Stockscreener
16.08
0.25%
-0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AUPH Giù?
Forum
Previsione
Frazionamento azionario
Aurinia Pharmaceuticals Inc Borsa (AUPH) Ultime notizie
Aurinia (NASDAQ: AUPH) officer to sell 47,000 shares for taxes - Stock Titan
Teva and Aurinia settle generics dispute over lupus drug, voclosporin - Life Sciences IP Review
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates - Eastern Progress
Zacks Investment ResearchGlobes - Globes - Israel Business News
Aurinia Secures Lupkynis Exclusivity Through 2036 in Teva Patent Settlement - finance.biggo.com
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises - Yahoo Finance UK
Bloom Burton Upgrades Aurinia Pharmaceuticals(AUPH.US) to Buy Rating, Raises Target Price to $21 - Moomoo
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug - Benzinga
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17 - Moomoo
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback - Yahoo Finance
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain - Yahoo Finance
Aurinia Pharmaceuticals and Teva Pharmaceuticals Resolve Patent Litigation Over Generic Voclosporin Capsules - Kalkine Media
AUPH Stock Rallies 6% After-Hours — Here’s Why - TradingView
Aurinia Settles Patent Lawsuit With Teva; Shares Rise After Hours - marketscreener.com
Aurinia, Teva Reach Voclosporin Patent Litigation Settlement - TipRanks
Aurinia stock falls on Teva patent settlement for voclosporin By Investing.com - Investing.com Canada
Aurinia stock falls on Teva patent settlement for voclosporin - Investing.com
Aurinia settles patent dispute with Teva over generic drug - Investing.com
Aurinia Settles Patent Litigation with Teva - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Aurinia Pharmaceuticals Inc (AUPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aurinia (AUPH) Latest Price Review: Rises 0.07% to $15.30 in the Current Update; Level Check: the Near-Term Reference Band Stretches From $14.54 to $16.07 under the Current SnapshotETF Outflow Streak - Vinanet
Aurinia (AUPH) Earnings Metrics: EPS Comes in Above Forecast in the Current Update; Trading-Day Reaction: Shares Move 0.07% UpQuarterly Profit Report - vinanet.vn
(AUPH) Risk Channels and Responsive Allocation - Stock Traders Daily
Aurinia Pharmaceuticals advances Lupkynis in ph... - Pluang
Aurinia Pharmaceuticals Doubles Down On Its Pipeline (NASDAQ:AUPH) - Seeking Alpha
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Navigating Growth in Biotech with a 10% Upside Potential - DirectorsTalk Interviews
Aurinia Pharmaceuticals (AUPH) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by Wall Street Zen to Buy - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Strong Q2 Earnings And Reaffirmed 2026 Guidance - simplywall.st
Aurinia Pharmaceuticals Announces Q2 2026 Financial Results with Strong Revenue and Income Growth - Kalkine Media
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates - Yahoo Finance
Aurinia Pharmaceuticals Inc. 2026: Revenue $83.22M, EPS $0.28— 10-Q Summary - TradingView
AUPH: Strong revenue and profit growth fueled by LUPKYNIS sales and disciplined capital allocation - TradingView
Aurinia Pharmaceuticals posts Q2 revenue $83.2M, net income $37.4M; reiterates 2026 guidance - TradingView
Aurinia Q2 revenue rises 19 percent to $83.2 million - Quiver Quantitative
AUPH: Strong revenue and net income growth driven by LUPKYNIS, with robust 2026 outlook - TradingView
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress - marketscreener.com
Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q2 Revenue $83.2M, Vs. FactSet Est of $80.4M - Moomoo
BRIEF-Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million - TradingView
(AUPH) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Uncovering a 16.68% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap Despite Its 50% Gain - simplywall.st
Lazard Asset Management LLC Sells 106,820 Shares of Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aurinia Pharmaceuticals Inc Revenue Breakdown – NASDAQ:AUPH - TradingView
Healthcare of Ontario Pension Plan Trust Fund Makes New Investment in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aurinia Pharma earnings up next as growth momentum faces test By Investing.com - Investing.com UK
OMERS ADMINISTRATION Corp Takes Position in Aurinia Pharmaceuticals Inc $AUPH - marketbeat.com
AUPH Q2'26 Earnings: EPS estimate is 0.24 USD - TradingView
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Strong Growth Potential with an 11.7% Upside - DirectorsTalk Interviews
Arrowstreet Capital Limited Partnership Sells 102,826 Shares of Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
AUPH|Aurinia Pharmaceuticals Inc|Price:15.215|Chg%:-0.135 - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AUPH|Aurinia Pharmaceuticals Inc|Price:14.880|Chg%:-0.120 - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Balance Sheet - TradingKey
AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors - Stocktwits
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a shareEarnings Preview - TradingView
Aurinia Pharmaceuticals Inc (AUPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aurinia Pharmaceuticals Inc. Revenue Breakdown – LS:A1W7D4 - TradingView
Aurinia Pharmaceuticals Inc (AUPH) Institutional Confidence - TradingKey
AUPH|Aurinia Pharmaceuticals Inc|Price:15.350|Chg%:+0.110 - TradingKey
AUPH|Aurinia Pharmaceuticals Inc|Price:15.400|Chg%:+0.160 - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Cash Flow - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AUPH Q2'26 Earnings: revenue estimate is 80.45M USD - TradingView
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):